Matthias Schiedel
Overview
Explore the profile of Matthias Schiedel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wurnig S, Huber M, Weiler C, Baltrukevich H, Merten N, Stotzel I, et al.
J Med Chem
. 2025 Feb;
68(4):4308-4333.
PMID: 39937529
Intracellular ligands of G protein-coupled receptors (GPCRs) are gaining significant interest in drug discovery. Here, we report the development of the fluorescent ligand Mz437 () targeting the CC chemokine receptor...
2.
Handke M, Beierlein F, Imhof P, Schiedel M, Hammann S
Anal Bioanal Chem
. 2024 Nov;
417(2):287-296.
PMID: 39570389
Lipids are major constituents of food but are also highly relevant substructures of drugs and are increasingly applied for the development of lipid-based drug delivery systems. Lipids are prone to...
3.
Schiedel M, Barbie P, Pape F, Pinto M, Unzue Lopez A, Mendez M, et al.
ChemMedChem
. 2024 Sep;
19(23):e202400543.
PMID: 39308157
The Frontiers in Medicinal Chemistry (FiMC) is the largest international Medicinal Chemistry conference in Germany and took place from March 17 to 20 2024 in Munich. Co-organized by the Division...
4.
Toy L, Huber M, Lee M, Bartolome A, Ortiz Zacarias N, Nasser S, et al.
ACS Pharmacol Transl Sci
. 2024 Jul;
7(7):2080-2092.
PMID: 39022357
In this study, we describe the structure-based development of the first fluorescent ligands targeting the intracellular allosteric binding site (IABS) of the CC chemokine receptor type 1 (CCR1), a G...
5.
Huber M, Wurnig S, Moumbock A, Toy L, Kostenis E, Bartolome A, et al.
ChemMedChem
. 2024 Jun;
19(20):e202400284.
PMID: 38932712
A conserved intracellular allosteric binding site (IABS) was recently identified at several G protein-coupled receptors (GPCRs). This target site allows the binding of allosteric modulators and enables a new mode...
6.
Vogt H, Shinkwin P, Huber M, Staffen N, Hubner H, Gmeiner P, et al.
ACS Pharmacol Transl Sci
. 2024 May;
7(5):1533-1545.
PMID: 38751637
The membrane protein family of G protein-coupled receptors (GPCRs) represents a major class of drug targets. Over the last years, the presence of additional intracellular binding sites besides the canonical...
7.
Spatz P, Chen X, Reichau K, Huber M, Muhlig S, Matsusaka Y, et al.
J Med Chem
. 2024 Apr;
67(8):6327-6343.
PMID: 38570909
The interleukin-8 receptor beta (CXCR2) is a highly promising target for molecular imaging of inflammation and inflammatory diseases. This is due to its almost exclusive expression on neutrophils. Modified fluorinated...
8.
Schiedel M, McArdle D, Padalino G, Chan A, Forde-Thomas J, McDonough M, et al.
J Med Chem
. 2023 Dec;
66(23):15801-15822.
PMID: 38048437
Schistosomiasis is a disease affecting >200 million people worldwide, but its treatment relies on a single agent, praziquantel. To investigate new avenues for schistosomiasis control, we have conducted the first...
9.
Sinatra L, Vogelmann A, Friedrich F, Tararina M, Neuwirt E, Colcerasa A, et al.
J Med Chem
. 2023 Oct;
66(21):14787-14814.
PMID: 37902787
Dysregulation of both tubulin deacetylases sirtuin 2 (Sirt2) and the histone deacetylase 6 (HDAC6) has been associated with the pathogenesis of cancer and neurodegeneration, thus making these two enzymes promising...
10.
Thomas A, Serafini M, Grant E, Coombs E, Bluck J, Schiedel M, et al.
ACS Chem Biol
. 2023 Oct;
18(11):2405-2417.
PMID: 37874862
Target validation remains a challenge in drug discovery, which leads to a high attrition rate in the drug discovery process, particularly in Phase II clinical trials. Consequently, new approaches to...